Benazepril is an ACE inhibitor prodrug used to treat hypertension. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor.
- Mechanism
- Curator reviewed
Benazeprilat, the active metabolite of Benazepril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion.
- Primary indication
- Benazepril is indicated for the treatment of hypertension.Curator reviewed · 6 structured indications
- Formula / weight
- C24H28N2O5 · 424.4895 g/mol (avg)
- First approval
- Canada, 1997 · United States, 1991
- Code names
- C09AA07 · CGS-14824A
- Brand names
Resolves to
XPCFTKFZXHTYIP-PMACEKPBSA-NSMILES[H][C@@]1(CCC2=CC=CC=C2N(CC(O)=O)C1=O)N[C@@H](CCC1=CC=CC=C1)C(=O)OCCWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Benazepril, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account